REG - Haleon PLC - Director/PDMR Shareholding

HALEONAnnouncement

18/05/2026 14:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260518:nRSR7691Ea&default-theme=true

RNS Number : 7691E  Haleon PLC  18 May 2026

 

 Haleon plc: Director/PDMR Shareholding

 

18 May 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today
announces notification and public disclosure in accordance with the
requirements of The UK Market Abuse Regulation of Transactions by a Person
Discharging Managerial Responsibilities ("PDMR").

 

On 15 May 2026, the Company received notification of the following transaction
as detailed below.

 

 1       Details of the issuer, emission allowance market participant

 a)      Name                                  Haleon plc

 b)      LEI                                   549300PSB3WWEODCUP19

 2       Reason for the notification

 a)      Position/status                       Senior Independent Non-Executive Director

 b)      Initial notification /Amendment       Initial Notification

 3       Details of the person discharging managerial responsibilities / person closely

       associated ("PCA")

 a)      PDMR/PCA                              PDMR

 b)      Name                                  Alan Stewart

 4       Details of the transaction(s): section to be repeated for (i) each type of

       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
         place where transactions have been conducted

 a)      Description of Instrument             Share

         Identification code                   GB00BMX86B70

 b)      Nature of the transaction             Acquisition of Ordinary Shares as a result of dividend reinvestment

 c)      Currency, Price(s) and volume(s)

                                                                  Price(s)           Volume(s)
                                                                  £3.3105            498

 d)      Aggregated information

         - Aggregated volume                   N/A

         - Price

 e)      Date of the transaction               14 May 2026

 f)      Place of the transaction              London Stock Exchange (XLON) 

 

 

 

Amanda Mellor

Company Secretary

 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better
everyday health. Our people, our brands, our research, our investment and our
innovation are aimed at improving the everyday health of consumers. Our
product portfolio spans six major categories - Oral Health, Vitamins, Minerals
and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and
Therapeutic Skin Health and Other. Our superior brands - such as Advil,
Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and
Voltaren - are trusted by more than one billion consumers and are recommended
by health professionals around the world.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBDGDUIUBDGLI



            Copyright 2019 Regulatory News Service, all rights reserved